✦ LIBER ✦

QOL benefits observed as early as week 2 with peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV

✍ Scribed by T.I. Hassanien; W.G.E. Cooksley; M. Sulkowski; C. Smith; G. Marinos; M.-Y. Lai; G. Pastore; R. Trejo-Estrada; A. Horta; E. Vale; N.S. Winfield; M. Neary; J. Green

Book ID: 118565304
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 112 KB
Volume: 36
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(02)80388-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon alfa-2A (40KD) (PEGASYS) p

Peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)

✍ S. Fargion; M. Borzio; A. Cargnel 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 312 KB

Re-treatment of interferon (IFN) plus ri

Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) Alfa-2A (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN Alfa-2A (Roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study

✍ S. Brillanti; A. Mangia; L. Cimino; A. Civolani; F. Fatuzzo; L. Fenoglio; M. Lev 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 166 KB

475 Sustained virological response (SVR)

475 Sustained virological response (SVR) to peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (Roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC)

✍ S. Fargion; M. Borzio; A. Maraschi; A. Cargnel 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 61 KB

1194 End of treatment and sustained resp

1194 End of treatment and sustained response to peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) (COPEGUS) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2A (ROFERON-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC)

✍ FARGION, S; BORZIO, M; CARGNEL, A 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

A comparison of cost-effectiveness of pe

A comparison of cost-effectiveness of peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitus C (CHC)

✍ S.D. Sullivan; J. Green; K.K. Patel; A. Crtaxi; A. Alberti; G. Giuliani; C. De C 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 319 KB

92 Final week-72 results of the aids peg

92 Final week-72 results of the aids pegasys ribavirin international co-infection trial (APRICOT): A randomized, partially blinded, multinational comparative trial of peginterferon ALFA-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon ALFA-2A(IFN)

✍ F.J. Torriani; J. Rockstroh; M. Rodriguez-Torres; E. Lissen; J. Gonzalez; A. Laz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB